Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Diagnosing Barth syndrome just got faster and more precise. Advances in genetic testing — including whole exome and genome sequencing now completed in as little as 8 days for $3,000 — have dramatically cut the time it takes to identify this rare condition. Cardiolipin profiling is also emerging as a key tool to confirm diagnoses and resolve uncertain genetic findings.
Barth syndrome, a rare X-linked genetic disorder affecting the heart and muscles, has historically taken years to diagnose. But the landscape is shifting fast. Whole exome and whole genome sequencing can now be completed in as little as 8 days at a cost of around $3,000 — compressing what was once a years-long diagnostic odyssey down to months.
Experts also highlight the limitations of disease-specific gene panels, noting that the TAZ gene (responsible for Barth syndrome) may not always appear on standard panels. Cardiolipin profiling has emerged as a powerful complementary tool — not only confirming the diagnosis but also helping resolve variants of uncertain significance (VUS).
Key Takeaways:
Why it matters: Earlier and more accurate diagnosis of Barth syndrome means patients — often young boys with cardiomyopathy — can access appropriate care sooner, potentially preventing life-threatening complications.